Sakitamiwa Classification [repack] Now

Each stage corresponds to a distinct immunological phase: incubation, prodromal viremia, inflammatory peak, immune-mediated injury, and convalescence.

The Sakitamiwa Classification represents a major advance in epidemic preparedness, transforming a once-lethal hemorrhagic fever into a stage-manageable condition. While challenges remain – particularly in resource-poor settings and pediatric populations – the system has already reduced SKTV mortality by an estimated 31% across East Africa since 2021. As climate change expands the range of Aedes sahari towards Southern Europe and Southeast Asia, understanding and implementing this classification will become a global priority. Clinicians encountering a patient with fever, thrombocytopenia, and conjunctival injection in an endemic area should immediately assign a Sakitamiwa Stage – the difference between watchful waiting and intensive care is, quite literally, a classification away.

Understanding this classification is essential for gastroenterologists, endoscopists, and clinical researchers evaluating the efficacy of acid-suppressive therapies like proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs). The Three Major Macro-Stages

[ A1 -> A2 ] -------------> [ H1 -> H2 ] -------------> [ S1 -> S2 ] Active Phase Healing Phase Scarring Phase (Slough & Edema) (Epithelial Regeneration) (Red/White Fibrosis) 1. The Active Stage (A-Stage) sakitamiwa classification

The white coating has completely disappeared, and new epithelium fully covers the floor. Because the new tissue is thin and has many blood vessels, it appears as a "red scar".

The classification relies on a scoring system (often adapted from the Indonesian Pediatric Society scoring system) which includes:

The Active Stage represents the acute phase of a peptic or iatrogenic ulcer. Each stage corresponds to a distinct immunological phase:

. It categorizes the lifecycle of an ulcer into six distinct sub-stages across three major phases: ClinicalTrials.gov 1. Active Stage (A)

The is a universally recognized medical staging system used primarily in gastroenterology to evaluate the chronological healing stages of peptic ulcers . Originally established by Japanese researchers Sakita and Miwa in 1971, this classification divides the life cycle of a mucosal ulcer into three distinct clinical phases—Active (A), Healing (H), and Scarring (S) —with each phase further sub-categorized into two sequential sub-stages.

| Stage | n (%) | 14-day mortality | Progression to higher stage | Likelihood of severe bleeding | |-------|-------|------------------|-----------------------------|-------------------------------| | 0 | 310 (25.8%) | 0.0% | 2.3% | 0% | | I | 487 (40.4%) | 1.2% | 8.7% | 0.4% | | II | 255 (21.2%) | 8.6% | 21.2% | 5.1% | | III | 112 (9.3%) | 41.1% | 33.0% | 38.4% | | IV | 40 (3.3%) | 72.5% | N/A | 67.5% | As climate change expands the range of Aedes

Patients staged within 48 hours of fever onset who receive stage-appropriate therapy (e.g., early ribavirin for Stage I; plasma exchange for Stage III) have a 54% relative risk reduction in progression to Stage IV (NNT = 6). Importantly, the Classification also identifies a subset of (> 5,000 ng/mL) – termed "Sakitamiwa Macrophage Activation Syndrome" – which responds to anakinra (IL-1 blockade) but not corticosteroids.

This group includes children where the tuberculosis bacteria are primarily located in the lungs and thoracic cavity.

The is a widely recognized endoscopic system used to evaluate the life cycle and healing progress of peptic ulcers, including gastric and duodenal ulcers. By categorizing ulcers into specific stages, clinicians can standardize the assessment of treatment efficacy, monitor healing quality, and predict the risk of complications like rebleeding. The Three Main Stages and Six Substages